Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12428 | 0.90 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 | |
| SCHEMBL891407 | 0.89 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 | |
| SCHEMBL14956919 | 0.88 | ALDH1A1 (0.55) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 | |
| SCHEMBL9011867 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 | |
| SCHEMBL14015788 | 0.86 | ESR1 (0.56) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 | |
| SCHEMBL13308494 | 0.86 | ESR1 (0.56) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 | |
| SCHEMBL11956138 | 0.86 | ESR1 (0.56) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 | |
| SCHEMBL17484853 | 0.86 | ESR1 (0.56) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 | |
| SCHEMBL14382370 | 0.86 | ESR1 (0.56) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 | |
| SCHEMBL2713160 | 0.86 | ESR1 (0.56) | SMN1; SMN2L3MBTL1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20230152695-A1 | RESIST UNDERLAYER FILM MATERIAL, PATTERNING PROCESS, AND METHOD FOR FORMING RESIST UNDERLAYER FILM | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-109477109-B | Oligonucleotide analogs targeting human LMNA | 萨勒普塔医疗公司 | 2022-09-23 | — | — | CN | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| CN-109477109-A | Target the oligonucleotide analogs of people LMNA | 萨勒普塔医疗公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2016204153-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | 宇部興産株式会社 | 2016-12-22 | — | — | WO | disclosed |
| EP-3056507-A1 | C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2016-08-17 | — | — | EP | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011140425-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1373233-B1 | DERIVATIVES OF N-(ARYLSULFONYL)BETA-AMINOACIDS COMPRISING A SUBSTITUTED AMINOMETHYL GROUP, THE PREPARATION METHOD THEREOF AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | SMN1; SMN2 3040/4885L3MBTL1 1734/4885KMT2A 2850/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | SMN1; SMN2 1198/4885L3MBTL1 4783/4885KMT2A 2425/4885 |
| US-20090215899-A9 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | SMN1; SMN2 3040/4885L3MBTL1 1734/4885KMT2A 2850/4885 |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | SMN1; SMN2 831/4885L3MBTL1 4548/4885KMT2A 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.